Stifel Nicolaus analyst Derek Archila reiterated a Buy rating on NGM Biopharmaceuticals (NGM) yesterday. The company’s shares closed last Wednesday at $24.45, close to its 52-week high of $25.09.
According to TipRanks.com, Archila is a 4-star analyst with an average return of 12.2% and a 50.0% success rate. Archila covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Madrigal Pharmaceuticals, and Alexion Pharmaceuticals.
NGM Biopharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $33.67.
See today’s analyst top recommended stocks >>
The company has a one-year high of $25.09 and a one-year low of $9.25. Currently, NGM Biopharmaceuticals has an average volume of 146.5K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
NGM Biopharmaceuticals, Inc. engages in the discovery and development of therapeutics for major diseases with an initial focus on cardio-metabolic and liver diseases. Its portfolio if composed of product candidates which focuses on non-alcoholic steatohepatitis, type 2 diabetes, obesity, oncology and age-related macular degeneration. The company was founded by Jin-Long Chen in 2008 and is headquartered in South San Francisco, CA.
